193 related articles for article (PubMed ID: 22001392)
1. AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia.
Motiwala T; Zanesi N; Datta J; Roy S; Kutay H; Checovich AM; Kaou M; Zhong Y; Johnson AJ; Lucas DM; Heerema NA; Hagan J; Mo X; Jarjoura D; Byrd JC; Croce CM; Jacob ST
Blood; 2011 Dec; 118(23):6132-40. PubMed ID: 22001392
[TBL] [Abstract][Full Text] [Related]
2. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
Motiwala T; Kutay H; Zanesi N; Frissora FW; Mo X; Muthusamy N; Jacob ST
Leukemia; 2015 Jun; 29(6):1350-9. PubMed ID: 25482129
[TBL] [Abstract][Full Text] [Related]
3. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia.
Sivina M; Hartmann E; Vasyutina E; Boucas JM; Breuer A; Keating MJ; Wierda WG; Rosenwald A; Herling M; Burger JA
Leukemia; 2012 Aug; 26(8):1812-20. PubMed ID: 22460735
[TBL] [Abstract][Full Text] [Related]
4. The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia.
Wakim J; Arman E; Becker-Herman S; Kramer MP; Bakos E; Shachar I; Elson A
Oncogene; 2017 Jun; 36(26):3686-3694. PubMed ID: 28166196
[TBL] [Abstract][Full Text] [Related]
5. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL.
Pekarsky Y; Palamarchuk A; Maximov V; Efanov A; Nazaryan N; Santanam U; Rassenti L; Kipps T; Croce CM
Proc Natl Acad Sci U S A; 2008 Dec; 105(50):19643-8. PubMed ID: 19064921
[TBL] [Abstract][Full Text] [Related]
6. PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.
Motiwala T; Majumder S; Ghoshal K; Kutay H; Datta J; Roy S; Lucas DM; Jacob ST
J Biol Chem; 2009 Jan; 284(1):455-464. PubMed ID: 18997174
[TBL] [Abstract][Full Text] [Related]
7. Lyn kinase and ZAP70 are substrates of PTPROt in B-cells: Lyn inactivation by PTPROt sensitizes leukemia cells to VEGF-R inhibitor pazopanib.
Motiwala T; Datta J; Kutay H; Roy S; Jacob ST
J Cell Biochem; 2010 Jul; 110(4):846-56. PubMed ID: 20564182
[TBL] [Abstract][Full Text] [Related]
8. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
[TBL] [Abstract][Full Text] [Related]
9. Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL.
Chen SS; Claus R; Lucas DM; Yu L; Qian J; Ruppert AS; West DA; Williams KE; Johnson AJ; Sablitzky F; Plass C; Byrd JC
Blood; 2011 Jan; 117(3):862-71. PubMed ID: 21098398
[TBL] [Abstract][Full Text] [Related]
10. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state.
Herling M; Patel KA; Khalili J; Schlette E; Kobayashi R; Medeiros LJ; Jones D
Leukemia; 2006 Feb; 20(2):280-5. PubMed ID: 16341048
[TBL] [Abstract][Full Text] [Related]
11. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.
Bresin A; Callegari E; D'Abundo L; Cattani C; Bassi C; Zagatti B; Narducci MG; Caprini E; Pekarsky Y; Croce CM; Sabbioni S; Russo G; Negrini M
Oncotarget; 2015 Aug; 6(23):19807-18. PubMed ID: 26090867
[TBL] [Abstract][Full Text] [Related]
12. Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.
Motiwala T; Majumder S; Kutay H; Smith DS; Neuberg DS; Lucas DM; Byrd JC; Grever M; Jacob ST
Clin Cancer Res; 2007 Jun; 13(11):3174-81. PubMed ID: 17545520
[TBL] [Abstract][Full Text] [Related]
13. Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies.
Gaudio E; Spizzo R; Paduano F; Luo Z; Efanov A; Palamarchuk A; Leber AS; Kaou M; Zanesi N; Bottoni A; Costinean S; Rassenti LZ; Nakamura T; Kipps TJ; Aqeilan RI; Pekarsky Y; Trapasso F; Croce CM
Blood; 2012 Jan; 119(1):180-7. PubMed ID: 22065599
[TBL] [Abstract][Full Text] [Related]
14. CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation.
Efanov A; Zanesi N; Nazaryan N; Santanam U; Palamarchuk A; Croce CM; Pekarsky Y
Leukemia; 2010 May; 24(5):970-5. PubMed ID: 20357824
[TBL] [Abstract][Full Text] [Related]
15. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.
Bichi R; Shinton SA; Martin ES; Koval A; Calin GA; Cesari R; Russo G; Hardy RR; Croce CM
Proc Natl Acad Sci U S A; 2002 May; 99(10):6955-60. PubMed ID: 12011454
[TBL] [Abstract][Full Text] [Related]
16. Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.
Greene JT; Mani R; Ramaswamy R; Frissora F; Yano M; Zapolnik K; Harrington B; Wasmuth R; Tran M; Mo X; McKenna M; Rangnekar VM; Byrd JC; Bondada S; Muthusamy N
Blood Adv; 2019 Apr; 3(8):1255-1266. PubMed ID: 30987970
[TBL] [Abstract][Full Text] [Related]
17. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.
Zanesi N; Aqeilan R; Drusco A; Kaou M; Sevignani C; Costinean S; Bortesi L; La Rocca G; Koldovsky P; Volinia S; Mancini R; Calin G; Scott CP; Pekarsky Y; Croce CM
Cancer Res; 2006 Jan; 66(2):915-20. PubMed ID: 16424025
[TBL] [Abstract][Full Text] [Related]
18. Stimulation of B-Raf increases c-Jun and c-Fos expression and upregulates AP-1-regulated gene transcription in insulinoma cells.
Langfermann DS; Rössler OG; Thiel G
Mol Cell Endocrinol; 2018 Sep; 472():126-139. PubMed ID: 29225069
[TBL] [Abstract][Full Text] [Related]
19. A Sleeping Beauty screen reveals NF-kB activation in CLL mouse model.
Zanesi N; Balatti V; Riordan J; Burch A; Rizzotto L; Palamarchuk A; Cascione L; Lagana A; Dupuy AJ; Croce CM; Pekarsky Y
Blood; 2013 May; 121(21):4355-8. PubMed ID: 23591791
[TBL] [Abstract][Full Text] [Related]
20. Restriction to Fos family members of Trip6-dependent coactivation and glucocorticoid receptor-dependent trans-repression of activator protein-1.
Diefenbacher M; Sekula S; Heilbock C; Maier JV; Litfin M; van Dam H; Castellazzi M; Herrlich P; Kassel O
Mol Endocrinol; 2008 Aug; 22(8):1767-80. PubMed ID: 18535250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
